Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Cannovum Cannabis AG is a prominent player in the pharmaceutical industry, focusing on the cultivation, distribution, and sale of high-quality medical cannabis products. The company's primary purpose is to provide healthcare professionals and patients with reliable and regulated access to cannabis for therapeutic use. By adhering to stringent quality control standards and leveraging advanced agricultural technologies, Cannovum Cannabis AG ensures that its products meet the highest safety and efficacy benchmarks. Operating in a sector growing rapidly due to changing legislation and increasing acceptance of cannabis-based treatments, Cannovum Cannabis AG has strategically positioned itself to capitalize on these trends. The company serves a diverse clientele, including pharmacies, healthcare providers, and other medical institutions across various regions in Europe and beyond. Cannovum Cannabis AG's role in the market is significant, as it contributes to the evolving landscape of the pharmaceutical industry by providing alternative treatment options that align with modern healthcare needs. Through innovation and compliance, Cannovum Cannabis AG continues to expand its footprint in the burgeoning global cannabis market.
€0.51
+€0.01 (+1.20%)
EOD Aug 7, 2026
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
▼ -100.0% YoY
Net Income (TTM)
-€401K
▲ +87.3% YoY
Op. Margin
—
ROIC
-36.57%
▲ +153.0pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
N/A
Cash & Equiv.
N/A
Continue Research
Cannovum Cannabis (27N0.XETR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cannovum Cannabis scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Cannovum Cannabis scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 2 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -36.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh 27N0.XETR's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.